A study has recently revealed that men who lack a certain gene subtype may be more susceptible to treatment-resistant prostate cancer. Researchers from Cleveland Clinic confirmed for the first time a mechanistic link between the gene HSD17B4 and deadly aggressive prostate cancer. The team built upon their earlier seminal work in which they discovered that a gene called HSD3B1 when altered enables prostate tumors to evade treatment and proliferate. They went on to show that the presence of this gene variant does in fact change treatment outcomes and overall survival in men. Lead researcher Nima Sharifi explained that they studied
